BEVACIZUMAB

Course overview

BEVACIZUMAB IS A HUMANIZED MONOCLONAL ANTIBODY AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR A (VEGF-A) AND IS USED FOR THE TREATMENT OF SEVERAL DIFFERENT CANCERS. ITS USE IS USUALLY IN COMBINATION WITH OTHER CHEMOTHERAPY AGENTS. THIS ACTIVITY WILL HIGHLIGHT THE MECHANISM OF ACTION, ADVERSE EVENT PROFILE, AND OTHER KEY FACTORS (E.G., OFF-LABEL USES, DOSING, PHARMACODYNAMICS, PHARMACOKINETICS, MONITORING, RELEVANT INTERACTIONS) PERTINENT FOR MEMBERS OF THE INTERPROFESSIONAL TEAM IN THE TREATMENT OF PATIENTS WITH BEVACIZUMAB.